210 related articles for article (PubMed ID: 33277315)
1. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
[TBL] [Abstract][Full Text] [Related]
2. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
5. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
6. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
7. Sulindac, 3,3'-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis.
Femia AP; Soares PV; Luceri C; Lodovici M; Giannini A; Caderni G
BMC Cancer; 2015 Sep; 15():611. PubMed ID: 26335331
[TBL] [Abstract][Full Text] [Related]
8. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.
Williamson T; Bai RY; Staedtke V; Huso D; Riggins GJ
Oncotarget; 2016 Oct; 7(42):68571-68584. PubMed ID: 27612418
[TBL] [Abstract][Full Text] [Related]
9. Multiple mucin depleted foci, high proliferation and low apoptotic response in the onset of colon carcinogenesis of the PIRC rat, mutated in Apc.
Femia AP; Luceri C; Soares PV; Lodovici M; Caderni G
Int J Cancer; 2015 Mar; 136(6):E488-95. PubMed ID: 25257656
[TBL] [Abstract][Full Text] [Related]
10. The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC(Min/+) mice.
Wang R; Wang Y; Gao Z; Qu X
Drug Discov Ther; 2014 Feb; 8(1):25-32. PubMed ID: 24647155
[TBL] [Abstract][Full Text] [Related]
11. Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Ravillah D; Mohammed A; Qian L; Brewer M; Zhang Y; Biddick L; Steele VE; Rao CV
J Pharmacol Exp Ther; 2014 Jan; 348(1):59-68. PubMed ID: 24218540
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
13. [Sulindac in familial adenomatous polyposis coli--preliminary findings of a prospective study].
Müller A; Hürlimann R; Meyenberger C; Staub P; Kobler E; Ammann R
Schweiz Med Wochenschr; 1994 Apr; 124(15):651-4. PubMed ID: 8191270
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
[TBL] [Abstract][Full Text] [Related]
16. Effect of sulindac treatment for attenuated familial adenomatous polyposis with a new germline APC mutation at codon 161: report of a case.
Esaki M; Matsumoto T; Mizuno M; Kobori Y; Yoshimura R; Yao T; Iida M
Dis Colon Rectum; 2002 Oct; 45(10):1397-402; discussion 1402-6. PubMed ID: 12394442
[TBL] [Abstract][Full Text] [Related]
17. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.
Matsumoto T; Nakamura S; Esaki M; Yao T; Iida M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):251-7. PubMed ID: 16460482
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model.
Hardiman KM; Liu J; Feng Y; Greenson JK; Fearon ER
PLoS One; 2014; 9(4):e96023. PubMed ID: 24763434
[TBL] [Abstract][Full Text] [Related]
19. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.
Guldenschuh I; Hurlimann R; Muller A; Ammann R; Mullhaupt B; Dobbie Z; Zala GF; Flury R; Seelentag W; Roth J; Meyenberger C; Fried M; Hoppeler T; Spigelman AD; Scott RJ
Dis Colon Rectum; 2001 Aug; 44(8):1090-7; discussion 1097-9. PubMed ID: 11535846
[TBL] [Abstract][Full Text] [Related]
20. Novel cell culture model for prevention of carcinogenic risk in familial adenomatous polyposis syndrome.
Telang N; Katdare M
Oncol Rep; 2009 Apr; 21(4):1017-21. PubMed ID: 19288003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
